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ABSTRACT
Objective: Momordica charantia (MC) (bitter gourd) is known traditionally to possess medicinal values. This edible vegetable is known for its anti-
inflammatory properties and has been studied for its bronchospasm preventive action. With the recent development in nanoformulations, this study 
was done to identify the effectiveness of MC nanoformulation in comparison to crude MC formulation in protecting animal from histamine-induced 
bronchospasm.
Methods: The optimized MC nanoformulation was prepared with polyethylene glycol and soy phosphatidylcholine. The MC crude powder was 
prepared by drying in hot air oven and grinding in a blender. Eight guinea pigs of both sexes were given once daily MC nanoformulation per oral 
by mixing with water for 7 days. Evaluation of the formulation was done on the 2nd, 4th, and 6th h on day 1 and day 7 after administration of MC for 
protection in developing pre-convulsive dyspnea due to histamine-induced bronchospasm.
Results: An analysis of variance test revealed statistically significant results in the protection of animals from developing bronchospasm after 
treatment with the MC nanoformulation in comparison to the control values. About 75% of animals were protected from developing bronchospasm 
on day 7 attributing to the cumulative effect of nanoformulation.
Conclusion: The study proved that the MC nanoformulation could effectively prevent histamine-induced bronchospasm in guinea pigs.
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INTRODUCTION
Momordica charantia (MC) also known as bitter gourd is a common 
edible vegetable, known to possess medicinal values [1]. It is 
traditionally known for its medicinal properties such as anti-diabetic, 
anticancer, anti-inflammation, antivirus, and for cholesterol-lowering 
effects. It contains many phenol compounds that may have the potential 
as antioxidant and anti-mutagen [2]. The fruit, stems, leaves, and roots 
of MC have all been used in traditional medicine to help treat ailments 
such as hyperlipidemia, digestive disorders, microbial infections, and 
menstrual problems [3]. Studies have also shown that bitter melon has 
anticarcinogenic properties and can be used as a cytotoxic agent [4]. 
Many studies had confirmed the electrolyte balancing property, anti-
inflammatory, and antioxidant property of MC with cytokine-inhibiting 
activity [5,6]. The anti-inflammatory activity of MC has been confirmed 
by its action through, interleukin 1 (IL)-1, IL-2, IL-6, IL-8, tumor necrosis 
factor-α, and nuclear factor kappa β normalization both in animal and 
human studies.
Asthma is a chronic inflammatory disorder of the airways and needs 
long-term use of anti-inflammatory drugs to control symptoms [7]. MC is 
known for its anti-inflammatory action and previous done have proven 
its property to prevent histamine-induced bronchospasm. However, 
no studies have been done on the nanoformulation of MC. This study 
was proposed as an attempt to prove the benefitting properties of MC 
nanoformulation pre-clinically in guinea pigs for its anti-inflammatory 
potent action in preventing histamine-induced bronchospasm.
The purpose of this study was to maximize the pharmacological 
property of the MC nanoformulation by making it available for maximum 
systemic absorption. As there is variation in the various extracts and 
powders of MC, there is probably variation in the formulation we 
provide to the patients. One such recent advance is the nanocapsule 
formulation [8]. They are considered as weapons of new drug delivery 
system. Hence, this study was proposed to identify the effectiveness of 
MC nanoformulation in protecting guinea pigs from histamine-induced 
bronchospasm in whole animal model.
METHODS
The study was done in two parts. First, the nanoformulation of MC and 
crude dry powder formulation of MC were prepared and shelf life of 
the two compounds was tested for 180 days. The second part of the 
study dealt with administration of the nanoformulation of MC per 
oral in guinea pigs and its efficacy in preventing histamine-induced 
bronchospasm was evaluated.
Preparation of nanoformulation of MC
MC crude powder was prepared by drying in hot air oven and 
grinding in a blender. Nanosuspension of crude bitter gourd powder 
was prepared by probe sonication and lyophilization technique 
[9,10]. Briefly, sufficient quantity (10 g) of crude bitter gourd powder 
was weighed and added to the aqueous phase (water) containing 
surfactant soy phosphatidylcholine. The aqueous mixture was 
sonicated using a bath sonicator for 15 min to get a homogeneous 
mixture. The resulting homogeneous mixture was sonicated 
using an ultrasonic probe sonicator (Vibra Sonics) for 30 min at 
20,000 Hz to produce bitter gourd nanosuspension. This sample of 
nanosuspension particle size was measured using Malvern Zetasizer 
(Nano ZS90, Malvern Instruments) at 25°C and measured 291.3 
diameter nanometer (d. nm). To improve the bioavailability of this 
MC nanoproduct, we added polyethylene glycol (PEG) and deep 
freezing was done at −80°C for 4 h following this, the sample was 
again freeze-dried in a lyophilizer (Lyodel) at a temperature and 
pressure of −50° and −1 bars, respectively, for 48 h to form powder. 
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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Research Article
138
Asian J Pharm Clin Res, Vol 12, Issue 8, 2019, 137-140
 Karthika et al. 
The dry nanoparticles were, hence, ready and the final particle size 
noted was 536.4 d. nm [11].
Following this, a 180 days stability test was done on both the 
formulations of MC, filled in gelatin capsules and found that both 
were stable in room temperature (25°) and high temperature (45°). 
Stability was tested for its color, shape, consistency, pH, weight, and 
disintegration in acid buffers.
Protection of histamine-induced bronchospasm by MC 
nanopowder (Fig. 1)
Eight adult guinea pigs of both sexes were chosen and the animals were 
kept in rooms under standard conditions. The animals were provided 
with ambient temperature of 25°C and 55% relative humidity, 12 h light 
period. Granular mixed feed and drinking water were available for all 
animals ad libitum throughout the experiment. The Institutional Animal 
Ethics Committee approved the study and the study was conducted 
strictly with guidelines of ICMR and CPCSEA.
On day 1, all the eight guinea pigs were weighed and animal dose of 
MC nanoformulation at 600 mg/kg and was administered orally after 
dissolving in drinking water. After 2 h, the animals were exposed to 2% 
histamine aerosol for 120 s using histamine chamber. Preconvulsive 
dyspnea (PCD) was noted in seconds [12,13]. The same experiment was 
repeated after 4 h from the time of MC nanoformulation administration 
and the PCD values were noted in seconds.
Following this, all the eight guinea pigs were given MC nanoformulation 
at 600 mg/kg/day (standardized animal dose) OD from day 2 to 
day 7. On day 7, the animals were again exposed to bronchospasm 
induction with 2% histamine aerosol chamber for 120 s from 2 h of MC 
nanoformulation administration. Bronchospasm protection activity for 
both the formulations of MC was observed. All the three sets of values 
to develop PCD (control value, day 1 value, and day 7 value) were 
tabulated for statistical analysis. The mean value for developing PCD 
in a control animal (before giving drug) was found to be 61.10 s [14].
RESULTS
The animals were administered with MC nanoformulation from day 1 to 
day 7 every day at 8 am. Protection for bronchospasm was observed on 
day 1 and day 7. The time to develop PCD was as follows:
On day 1, after 4 h from nanoformulation of MC administration, it was 
observed that 5 (62.5%) animals were completely protected from PCD 
and three animals had prolonged duration in developing PCD compared 
with the previous exposure at 2 h. (Further, exposure to histamine not 
done as >50% of animals were protected at the end of 4 h).
On day 7, six animals (75%) were completely protected from developing 
PCD, and hence, further, exposure to histamine was not done.
Statistical analysis
Analysis of variance (ANOVA) test was applied to compare the time 
difference to develop PCD in the animals in seconds between the three 
values (Day 1: 2 h and 4 h and day 7: 2 h).
ANOVA test done between the three values has effectively demonstrated 
that all the animals were significantly protected from developing 
bronchospasm on day 1 after 4 h of MC nanodrug formulation (p<0.01)*. 
Similarly, the animals were significantly protected from developing 
bronchospasm on day 7 after 2 h of drug administration (p<0.01)*.
Post-study animals were observed for a period of 2 months and no drug 
reactions or fatal effects were observed.
DISCUSSION
The aim of this study was to compare the efficacy and potency of MC nano 
dry formulation in contrast to its raw form as MC dry powder and MC 
fresh juice demonstrated by Bhuvaneswari et al. in animal model [14]. 
MC nanopowder was prepared and the particle size measurement 
showed 75% reduction in size of the particles in comparison to MC 
crude dry powder (Table 1). The nanoformulation was proved stable 
in high and low temperature after a 180 days stability testing (Table 2).
The mean of the control group was found to be 61.10 s [14]. Comparison 
was done for the same group animals on three different timings of 
histamine exposure post nanodrug administration and all the three sets 
of values were compared with ANOVA test (Table 3).
Guinea pigs being most sensitive for its histamine receptor sensitivity 
were chosen for this study [15]. Fig. 2 has clearly shown the number of 
animals protected from developing PCD. A normal control animal can 
hold from developing PCD for 61.1 s and animals treated with standard 
drug Montelukast could hold from developing PCD for 120 s, evinced 
from the previous studies [14].
Table 4 has illustrated that 50% of animals were able to attain 
protection from developing bronchospasm after 2 h of MC nano dry 
powder formulation administration. Following this, almost 100% 
of animals showed prolongation of duration from developing PCD 
in comparison to the control, hence, proving the bronchospasm 
protective activity of MC nanodrug. On the same day, 62.5% of animals 
were completely protected from developing PCD after 4 h of MC 
nanodrug administration on day 1 and further exposure to histamine 
Table 1: Particle size, polydispersion unit, and zeta potential of 







MC crude dry powder 3953 d. nm 1.000 −6.01
MC nano dry 
powder (SPL+PEG)
534.6 d. nm 0.612 −36.23
MC: Momordica charantia, PEG: Polyethylene glycol
Table 2: Physical properties of individual capsules from day 0 to day 180 at room temperature and high temperature
Capsules Color Odor Shape Consistency
MC crude dry powder Yellow+red capsule color was not altered No odor Shape maintained Dry capsules
MC nano dry powder (SPL+PEG) Yellow+red capsule color was not altered No odor Shape maintained Dry capsules
Table 3: ANOVA test between the time to develop PCD on day 1 at 2 h and 4 h and day 7 at 2 h with control value 
S. No. Group Mean Control 
(mean value)
SD of group Post hoc ANOVA between group 
and control
1. Day 1 (2 h) 69 61 20.1 0.496
2. Day 1 (4 h) 113.5 61 9.5 0.000* (p<0.01)
3. Day 7 (2 h) 116.6 61 6.3 0.000* (p<0.01)
ANOVA: Analysis of variance, PCD: Preconvulsive dyspnea
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was terminated on day 1. Tables 3 and 4 also illustrate cumulative 
doses of nanoformulation of MC given from day 1 to day 7 evidently 
showed that the effect was observed early. On day 7, 75% of animals 
were completely protected from PCD after 2 h of the nanoformulation 
administration (Fig. 2).
Statistical significance is shown with ANOVA test for a collective 
comparison between day 1 values at 2 h and 4 h and day 7 values at 
2 h. Post hoc ANOVA comparison was done with control values and 
three values, respectively. This demonstrated the statistical significance 
(p<0.01)* of animal protection from developing PCD at 4th h value of day 
1 and 2nd h value at day 7 (Table 3).
CONCLUSION
MC nanoformulation is found to be more efficient and potent in bringing 
pharmacological effect and protecting the animal from bronchospasm 
in comparison to MC dry powder and fresh juice. Nanoformulation 
is obtaining wide popularity in the pharmacotherapy for its better 
bioavailability, potency, and efficacy. MC being a natural product 
together with the optimization of the product into nanoparticles with 
Fig. 1: Study method to assess the potency of Momordica charantia dry powder and nano dry powder in whole animal model
Fig. 2: Time to develop preconvulsive dyspnea on day 1 
after 2 h and 4 h and day 7 after 2 h of Momordica charantia 
nanoformulation administration
Table 4: Time to develop PCD on day 1 after 2 h and 4 h and day 7 after 2 h of MC nanoformulation administration
S. No. Guinea pig Weight (g) PCD (s) after 2 h on day 1 PCD (s) after 4 h on day 1 PCD (s) after 2 h on day 7
1 G1 775 67 104 120
2 G2 700 95 120 120
3 G3 600 60 96 79
4 G4 500 43 108 104
5 G5 775 53 120 120
6 G6 800 58 120 120
7 G7 678 78 120 120
8 G8 850 100 120 120
Average PCD time 69.25 s 113.5 s 116.6 s
PCD: Preconvulsive dyspnea, MC: Momordica charantia
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PEG and soy phosphatidylcholine has proved to be a potent formulation 
than the crude dry powder. Hence, this study can become a future 
platform to compare MC nanoformulation as an adjuvant management 
in the standard care of treatment for bronchial asthma after effective 
clinical trials.
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